Aridis Pharmaceuticals, Inc.
ARDS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $3,821 | $7,933 | $9,553 | $21,523 |
| - Cash | $35 | $19 | $1,320 | $4,876 |
| + Debt | $4,840 | $6,295 | $3,946 | $6,130 |
| Enterprise Value | $8,626 | $14,209 | $12,179 | $22,777 |
| Revenue | $417 | $19,647 | $0 | $0 |
| % Growth | -97.9% | – | – | – |
| Gross Profit | $417 | $19,647 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$810 | $13,732 | -$6,176 | -$7,320 |
| % Margin | -194.2% | 69.9% | – | – |
| Net Income | -$83 | $12,144 | -$6,816 | -$6,387 |
| % Margin | -19.9% | 61.8% | – | – |
| EPS Diluted | -0.002 | 0.33 | -0.22 | -0.35 |
| % Growth | -100.7% | 250% | 37.1% | – |
| Operating Cash Flow | -$983 | -$4,343 | -$4,002 | -$8,557 |
| Capital Expenditures | $0 | $0 | $0 | -$49 |
| Free Cash Flow | -$983 | -$4,343 | -$4,002 | -$8,606 |